. In mammary carcinoma, not only the high incidence of Y 1 Rs of 85% in malignant primary human breast tumours and 100% in breast cancer derived lymph node metastases attracted special attention, but also the high receptor density. In-vitro autoradiography studies on tumour slices with [ 125 I]hPYY and non-radioactive, subtype-selective ligands for
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) are 36 amino acid peptides forming a family of biologically active peptides, the so-called neuropeptide Y or pancreatic polypeptide family 1 . Today, five mammalian NPY receptors (YRs) are known from molecular cloning, the Y 1 R, Y 2 R, Y 4 R, Y 5 R and y 6 receptor [2] [3] [4] . The y 6 receptor gene encodes a functionally active protein in mice, but is a pseudogene in humans and not present in the rat genome at all 3 . All five subtypes belong to the large superfamily of G-Protein Coupled Receptors (GPCRs) which are characterised as proteins located in the cell membrane consisting of seven transmembrane helices. The binding affinity of endogenous ligands is quite inhomogeneous: while NPY strongly binds to Y 1 R, Y 2 R and Y 5 R (EC 50 values in the single-digit nanomolar range) its affinity to the Y 4 R subtype is lower by at least two orders of magnitude. In contrast, PP is the only endogenous ligand binding to Y 4 R at low nanomolar concentrations 5 . NPY is one of the most abundant neuropeptides in the central and peripheral nervous system. It is involved in the regulation of numerous physiological and pathophysiological processes, such as gastro-intestinal regulation, food intake and blood pressure.
Recently, Y 1 R and Y 2 R have been found to be overexpressed in a number of different tumours, such as ovarian cancer (Y 1 R and Y 2 R) 6 , neuroblastoma (Y 2 R only) 7 or renal cell carcinomas (Y 1 R only) 8 . In mammary carcinoma, not only the high incidence of Y 1 Rs of 85% in malignant primary human breast tumours and 100% in breast cancer derived lymph node metastases attracted special attention, but also the high receptor density. In-vitro autoradiography studies on tumour slices with [ . Therefore, the Y 1 R is a promising target for tumour diagnosis and targeted tumour therapy, due to the high receptor expression and the predominance of the Y 1 R subtype in breast cancer tissue.
As subtype selective ligands are highly attractive for specific targeting of Y 1 R-positive tumours, many efforts have been made to design such subtype selective ligands. In 2001, the Beck-Sickinger group reported the first Y 1 R-preferring NPY analogues. [Phe 7 ,Pro 34 ]pNPY showed the highest selectivity for Y 1 R over Y 2 R and Y 5 R (>1:3000-fold) 10 . This compound was further developed towards a 99m
Tc-labelled radioligand, [ 99m Tc]Tc(CO) 3 -N α His-Ac-[Phe 7 ,Pro 34 ]-NPY, which was also used in first human imaging studies 11 . Based on this work, we have reported the first 18 18 F-fluoroglycosylation using the corresponding alkyne-functionalised peptide 12 .
Besides the peptidic NPY analogues, a number of non-peptide Y 1 R ligands have been reported, such as BIBP3226 13 , BIBO3304 14 , LY357897 15 and Y1-973 16 . The latter was radiolabelled with fluorine-18, a positron emitting radionuclide with beneficial decay characteristics, i.e. a half-life of 110 min, a clean decay profile (97% positron emission, 3% electron capture) and a low positron energy (max. 0.635 MeV), resulting a low maximum positron range of 2.4 mm in water and therefore leading to high-resolution positron emission tomography (PET) images 17 .
[ 18 F]Y1-973 was studied as the first non-peptide Y 1 R antagonist to be successfully applied for in vivo imaging of Y 1 R in the central nervous system (CNS) of monkeys 16 . However, this compound is most likely not suitable for peripheral imaging of breast cancer due to its high lipophilicity. The (R)-argininamide BIBP3226 was described as the first highly potent and selective Y 1 R antagonist in 1994 13 . Recently, we reported prototypic 18 F-labelled argininamide-type Y 1 R antagonists derived from BIBP3226 as candidate radioligands for PET (1-4, , the uptake of the compound in the kidneys was reduced by a factor of 10, being the major advantage of the hydrophobic small molecule antagonist PET radioligand.
Based on these findings, the aim of this study was to reduce the lipophilicity of a candidate ligand in order to achieve a more suitable biodistribution with reduced biliary excretion and thus a better visibility of the tumour in PET imaging studies. Therefore, we synthesised three BIBP3226-derivatives, two with 18 F-fluoroethoxy-linkers and one with an 18 F-fluoroglucosyl moiety, and compared their properties in vitro on MCF-7-Y1 cells and in vivo using a nude mouse tumour xenograft model.
Results and Discussion
chemistry and radiochemistry. The alkynylated labelling precursor 7 was prepared from amine 4 19 by guanidinylation of 4 with the isothiourea derivative 5 in the presence of mercury(II) chloride yielding intermediate 6, which was treated with trifluoroacetic acid (TFA) to obtain alkyne 7 (Fig. 1) . The latter was subjected to copper(I)-catalysed cycloadditions with azides 8 20 , 9 and 10 yielding the potential Y 1 R ligands 11-13 in a purity of >95% (Fig. 1) . In-vitro characterisation. For the determination of the Y 1 R affinities of 11, 12 and 13 (synthesis see Fig. 1 ), competition binding assays were carried out using the radioligand [ 3 H]UR-MK299 (K d = 44 pM) on SK-N-MC neuroblastoma cells as described previously 22 . K i values of 11-13 are provided in Table 1 together with reference values from literature for the previously published compounds 1-3 for comparison. The precursor alkyne 7 was found to bind to the Y 1 R with an affinity of 0.94 nM and thus exhibiting a similar receptor affinity as BIBP3226 and the fluoroacylated compound 1 previously published by Keller et al. (both K i = 1.3 nM) 18 . The 6-deoxy-6-fluoroglycosyl derivative 11 bound with an affinity of 208 nM to the Y 1 receptor, which is a 10-fold higher Y 1 R affinity compared to the 2-deoxy-2-fluoroglycosyl derivative 3 (K i = 2000 nM, Table 1 ) which had a longer spacer moiety between the fluoroglycosyl moiety and the binding motif 18 . Although exhibiting a lower affinity to the Y 1 R by a factor of about 200 compared to the lead compound BIBP3226, this finding supported our hypothesis, that shortening the linker from ten to only three atoms (3 vs. 11, Table 1 ) would result in a less pronounced decrease in Y 1 R affinity. Compared to the glycosyl derivatives, the compounds bearing the less polar fluoroethoxy groups revealed higher Y 1 R affinities: The K i value of 13 was determined to be 29 nM, which means that it has a sevenfold higher affinity than the fluoroglycosylated compound 11, and the affinity of ligand 12 comprising the short fluoroethoxy chain increased even more by one order of magnitude (K i = 2.8 nM).
To assess the YR subtype selectivity profiles of the three potential Y 1 R ligands 11, 12 and 13, the affinities to the other subtypes of the neuropeptide Y receptor, Y 2 R, Y 4 R and Y 5 R, were determined (Table S1 , Supplementary Information). None of the three compounds showed considerable binding to one of the other subtypes within the experimental range of concentrations (maximum concentration of 10 µM), confirming the subtype selectivity for Y 1 R of the ligands under study (11) (12) (13) .
The octanol-water distribution coefficients (logD 7.4 ) of the radioligands were determined by the "shake flask" method and revealed a weak lipophilicity for all three compounds, being in good accordance to the calculated b Experimental logD 7.4 values were determined by the "shake flask" method (n = 3, performed in triplicates).
c The binding to human plasma proteins was determined by means of gel filtration tubes (n = 3).
d
The stability of the radiotracers in human serum was determined by radio-HPLC (n = 1). Obviously, there was a strong influence of the bulkiness or hydrophilicity of the side chain on receptor affinity: The more hydrophilic or the more sterically demanding the side chain, the lower is the affinity to the Y 1 R. The results of the previously published ligands 1 (logD 7.4 = 2.34; K i = 1.3 nM) and 3 (clogD 7.4 = 0.37; K i = 20,000 nM) 18 support this hypothesis. The binding of the radioligands to human plasma proteins was determined by gel filtration and revealed a high fraction of protein bound radioligand: less than half of the amount of radioactivity in plasma was unbound and thus freely available in the blood (42% Table 2 ). The stability of the radiotracers was evaluated in vitro by radio-HPLC: None of the three radioligands showed any radioactive degradation products within 3 h of incubation in human serum at 37 °C (see Supplementary  Fig. S3 and Table 2 ).
To determine cellular accumulation in vitro, assays with the 18 F-labelled ligands were performed using the human breast cancer cells MCF-7-Y1. Cells were incubated either with the radioligand alone (total binding) or with the radioligand in the presence of 10 µM BIBP3226 as the blocking substance for determination of nonspecific binding. The total radioactivity in each well was defined as 100%. The highest specific accumulation was observed for the fluoroethoxy radioligand 11 were determined in the blood samples. The radioligands and radiometabolites showed fast clearance from the blood, as there was no detectable radioactivity in the blood at 90 min p.i. Moderate amounts of radioactivity were detected in the kidneys and intestines, and exceptionally high radioactivity was observed in the gall bladder (up to 600%ID/g after 90 min for [ 18 F]11). All other organs did not show any significant accumulation of the radioligands. The uptake in the liver as the main organ for metabolism of xenobiotics was below 5%ID/g at 30 min and below 1.5%ID/g at 90 min p.i. The three 18 F-radioligands revealed a more differentiated result regarding the uptake in the kidney, which can be ascribed to the formation of hydrophilic radiometabolites in the blood (Supplemantary Fig. S4 18 . The aim of reducing the uptake in the gall bladder by using more hydrophilic radioligand analogues, was obviously not reached, although the lipophilicity of the radiotracers was in fact reduced. Since only very little radioactivity was detected in the bones, it is most likely that there was no cleavage of fluoride from the molecules in terms of metabolism. www.nature.com/scientificreports www.nature.com/scientificreports/ Finally, PET imaging was performed with the three radiotracers on MCF-7-Y1 xenografted nude mice. However, despite low background, visualision of the tumour with the fluoroglycosylated radiotracer [
Biodistribution and small animal pet.
18 F]11 failed, most likely due to the low affinity of the radioligand to the Y 1 R (Fig. 6, left Supplementary Information Fig. S4 ). 18 F-labelled ligands under study. However, the PET imaging results suffered from high background levels, because of fast degradation of the radioligands in the blood and marked binding to plasma proteins. Therefore, the present study has to be regarded as another step towards the development of an optimal PET radioligand for Y 1 R imaging in vivo.
Methods
General. Radio-HPLC was performed on an Agilent 1100 system with a quarternary pump and a variable wavelength detector and a radio-HPLC detector D505TR (Canberra Packard). Computer analysis of the HPLC data was performed using FLO-One software (Canberra Packard). Electron-spray ionisation (ESI) mass spectrometry analysis was performed using a Bruker Esquire 2000 instrument.
chemistry. Synthetic procedures and analytical data for the guanidinylating reagent 5 and compounds 14-21 are described in the Supplementary Information associated with this article. The (R)-ornithine derivative 4 19 and the glycosyl azide 8 20 were prepared according to previously described procedures. 5-{[(1Z)-Amino({[({1-[2-(2-fluoroethoxy)ethyl]-1H-1,2,3-triazol-4-yl}methyl)carbamoyl]-imino})methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxyphenyl) methyl] pentanamide (12). 7 (5.54 mg, 10 µmol, 1 eq.) and 9 (6.00 mg, 45 µmol, 4.5 eq.) were dissolved in 380 µL tert-butanol and 232 µL water and added to a 3 mL micro reaction vessel. Solutions of copper(II) acetate (67.5 µL, 40 mM), sodium ascorbate (81.0 µL, 500 mM), THPTA (tris(3-hydroxypropyltriazolylmethyl)amine, 40 µL, 20 mM, in EtOH) and DIPEA (2 µL) were mixed for 1 min and then added to the reaction vessel. Acetonitrile (250 µL) was added to the reaction vessel and the solution was stirred for 5 min in the capped vessel. The mixture was diluted with 20 mL water and passed through a preconditioned (10 mL acetonitrile, 15 mL water) Sep-Pak ® C18 Plus Long SPE cartridge. The trapped product was eluted from the SPE cartridge with 2 mL ethanol and the solvent was evaporated in vacuo. The crude product was purified by semipreparative HPLC (Kromasil 100 C8 5 µm, 125 × 8 mm, 4 mL/min, 30-40% CH 3 CN (0.1% TFA) in water (0.1% TFA) in a linear gradient over 30 min, t R = 10.7 min). The fractions containing the product were pooled, concentrated in vacuo, coevaporated with acetonitrile several times and dried in vacuo.
Yield: 1.8 mg (26%); HPLC: t R = 3.85 min (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 10-90% CH 3 CN (0.1% TFA) in water (0.1% TFA) in a linear gradient over 10 min), 95%; t R = 2.96 min (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 25% CH 3 CN (0.1% TFA) for 1 min, then 25 18 F]fluoroglucosyl azide was prepared, isolated by semi-preparative HPLC and deacetylated with NaOH (250 µL, 60 mM, 10% ethanol) at 60 °C for 5 min as described before 20 . The crude product 6-deoxy-6-[ 18 F]fluoroglucosyl azide [ 18 F]8 was subsequently used for the click chemistry reaction with alkyne 7 in a one-pot-procedure as described before 21 . In brief, to the solution containing In-vitro characterisation of radiotracers. Lipophilicity determination. The lipophilicity of the radioligands was determined by the distribution coefficient logD 7.4 . The respective radioligand (10 µL, about 25 kBq) was added to a mixture of PBS (500 µL) and 1-octanol (500 µL) and the emulsion was vortexed for 1 min. After centrifugation 3 × 100 µL were taken of each layer and analysed by a γ-counter. www.nature.com/scientificreports www.nature.com/scientificreports/ radio-HPLC (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 0-1 min 25% CH 3 CN (0.1% TFA) in water (0.1% TFA), 1-6 min 25-60%, 6-7 min 60-100%, 7-8 min 100%).
(2R)-5-{[(1Z)-Amino[({[1-(2-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}ethyl)-1H-1,2,3-triazol-4-yl]methyl}carbamoyl)imino]methyl]amino}-2-(2,2-diphenylacetamido)-N-[(4-hydroxyphenyl)-methyl]pentanamide (13)
Cell line. MCF-7-Y1 is a subclone that originated in Prof. Dr. Armin Buschauer's group (Regensburg University, Regensburg) from human breast cancer cell line MCF-7 in the 157 th passage and shows 2-3 fold higher Y 1 R expression 25 . MCF-7-Y1 cells were cultivated in MEM Earle´s liquid medium with 2.2 g/L NaHCO 3 (Merck Biochrom, Darmstadt) containing 10% FBS and 1% L-glutamine. All cells were cultured under sterile conditions in a humidified atmosphere containing 5% CO 2 at 37 °C. Cells were routinely passaged twice a week.
Cellular accumulation assay.
The cellular accumulation of Y 1 R radioligands by MCF-7-Y1 cells was measured: On the day prior to the experiment, 300,000 cells per well were seeded into 24-well plates (Greiner Bio-One). Attached cells were washed twice with cold PBS and 450 µL of assay medium (cell culture medium containing 0.1% BSA) were added to the cells for total binding. For non-specific binding, 400 µL of assay medium and 50 µL of medium containing 10 µM BIBP3226 were added. Finally, 50 µL of medium containing approx. 15 kBq of the respective radiotracer were added to each well, and cells were incubated at 37 °C for 10, 30, 60 or 90 min. After incubation, cells were washed with 500 µL of ice-cold PBS and lysed with 600 µL of warm 1 M NaOH. The lysed cells were transferred to counting tubes and analysed in the γ-counter (Wallac Wizard, Perkin Elmer, Waltham, MA, USA). Separate tubes containing 50 µL of medium with the radiotracer (approx. 15 kBq) were analysed as reference samples. Experiments were performed in sextuplicate (n = 6).
In-vitro autoradiography. MCF-7-Y1 tumour bearing mice were sacrificed by cervical dislocation under deep isoflurane anesthesia and tumours were excised and subsequently frozen in a hexane/dry ice bath (−70 °C). MCF-7-Y1 tumour slices (14 µm) were prepared on a cryostat microtome HM 500 O (Microm, Walldorf) and thaw-mounted on Histobond ® adhesive glass slides (Marienfeld, Lauda-Königshofen).
For autoradiography studies slides were thawed and pre-incubated for 15 min in incubation buffer (50 mM TRIS HCl, pH 7.4, containing 120 mM NaCl, 5 mM MgCl 2 ,) at room temperature. Thereafter, 800 µL of incubation buffer, containing 0.1 MBq of the respective radiotracer were pipetted on the slide and incubated at room temperature for 60 min. For displacement studies BIBP3226 (1 µM or 10 µM) was added to the incubation buffer before pipetting on the slides. Afterwards slides were washed by placing in ice cold incubation buffer (3 × 2 min) followed by short dipping in ice cold distilled water. Slides were carefully dried in a stream of warm air and finally placed on an autoradiography film (Fuji Imaging Plate BAS-IP SR 2025 E, Fujifilm, Düsseldorf) overnight prior to readout (25 µm resolution) on the autoradiograph (HD-CR-35 Bio, Raytest, Straubenhardt) and analysis with the software AIDA (Raytest). Additional sections were stained with hematoxylin and eosin (H&E) for comparison with the autoradiography images.
In-vivo characterisation of radiotracers. All mouse experiments were approved by the local animal protection authorities (Government of Central Franconia, Germany, No. 55.2 2532-2-279) and performed at the FAU in accordance with the relevant E.U. guidelines and regulations.
Biodistribution. Biodistribution studies were conducted using female NMRI outbred mice (HsdWin:NMRI) purchased from Envigo (Horst, The Netherlands). Mice were kept in groups of four to five animals in individually ventilated cages in a twelve hours dark/light cycle with unlimited access to water and standard chow. At the age of eight to nine weeks six animals per radiotracer were injected with 2-4 MBq of the respective radiotracer under isoflurane anesthesia. Mice were sacrificed by cervical dislocation 30 or 90 min p.i. of the radiotracer. Blood as well as the organs/tissues lung, liver, kidneys, heart, spleen, brain, muscle, intestines, gall bladder and bones were harvested and analysed in the γ-counter. Samples were weighed and radioactivity in different tissues was calculated as percentage of the total injected dose per gram tissue (%ID/g).
Small animal PET.
For the NPY Y 1 R xenograft model, female NMRI nude mice (HsdCpb:NMRI-Foxn1 nu ) were purchased from Envigo (Horst, The Netherlands) at the age of three weeks. Mice were kept in groups of four to five animals in individually ventilated cages in a twelve hours dark/light cycle with unlimited access to water and standard chow. At the age of nine to ten weeks one 17β-estradiol pellet per animal (0.72 mg per pellet, 3 mm diameter) with a 60-day release time (Innovative Research of America, Sarasota, FL, USA) was subcutaneously implanted on the back under isoflurane anesthesia. After three days, approximately 10 6 MCF-7-Y1 tumour cells (in 50 µL PBS) were mixed with Matrigel (50 µL, BD Biosciences, Heidelberg) and then injected subcutaneously at the back. Tumour diameters and weight of the animals were recorded five times a week. Imaging studies were performed four weeks after inoculation of the cells.
Small animal PET scans were performed on an Inveon ™ microPET scanner (Siemens Healthcare, Erlangen) under isoflurane anesthesia (3%). Tumour bearing mice (26-35 g, n = 2-3 for each radioligand) were intravenously injected into the tail vein with the respective radiotracer (1.5-4.2 MBq in about 100 µL of saline) under isoflurane anesthesia (3-4%). Static images were acquired for 15 min starting 45 min p.i. of the radiotracer. For displacement studies, the same mice were co-injected with the radiotracer ([ www.nature.com/scientificreports www.nature.com/scientificreports/ Determination of radioactive metabolites of Y 1 R radioligands in mouse blood. Nude mice were anesthetised with isoflurane and injected with the respective radiotracer (3-25 MBq) into the tail vein. After 5 min, animals were sacrificed by cervical dislocation and approx. 100 µL blood were collected from the abdomen and transferred into Li-heparinised Microvettes ® (100 LH, Sarstedt). The same volume of aqueous urea (0.8 g/mL) was added and the Microvette ® was centrifuged (2000 × g, 5 min). The supernatant was transferred to a 1.5 mL reaction vial, mixed with the same volume of 10% aqueous TFA and centrifuged (20000 × g, 5 min). This step was repeated once. A sample of the resulting supernatant (100 µL) was analysed by radio-HPLC using two methods (Chromolith RP-18e, 100 × 4.6 mm, 4 mL/min, 0-1 min 25% CH 3 CN (0.1%TFA) in water (0.1%TFA), 1-6 min 25-60%, 6-7 min 60-100%, 7-8 min 100%; Kromasil 100 C8 5 µm, 250 × 4.6 mm, 1.5 mL/min, 1-25 min 20-53.3% CH 3 CN (0.1% TFA) in water (0.1% TFA), 25-27 min 53.3-80%, 27-28 min 80-100%, 28-32 min 100%).
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary Information files). Parts of this study have been reported in the PhD thesis 'Selective neuropeptide and opioid receptor radioligands for imaging studies in vivo by positron emission tomography (PET)' by Julian J. Ott 26 .
